Table 1

Initial characteristics of the 172 patients with primary myelofibrosis

CharacteristicValue
Patients, no. 172 
Age, y, median ± SD 65 ± 9.69 
Hemoglobin, g/L, median ± SD 104 ± 24.5 
White blood cell count, ×109/L, median ± SD 11.25 ± 14.26 
Platelet count, ×109/L, median ± SD 297 ± 276 
Abnormal cytogenetics* (%) 30 of 89 (34) 
Weight loss, n (%) 33 (19) 
Hepatomegaly, n (%) 76 (44) 
Male/female (ratio) 90/82 (1.1:1) 
Circulating blasts > 1%, n (%) 60 (36) 
Immature granulocytes > 5%, n (%) 109 (64) 
Treatment regimen, n (%)  
    Chemotherapy 84 (49) 
    Androgens 33 (19) 
    Splenectomy 28 (16) 
Lille score, n (%)  
    Low 78 (45) 
    Intermediate 77 (45) 
    High 17 (10) 
IWGMRT score,* n (%)  
    Low 18 (11) 
    Intermediate-low 51 (31) 
    Intermediate-high 56 (34) 
    High 39 (24) 
CharacteristicValue
Patients, no. 172 
Age, y, median ± SD 65 ± 9.69 
Hemoglobin, g/L, median ± SD 104 ± 24.5 
White blood cell count, ×109/L, median ± SD 11.25 ± 14.26 
Platelet count, ×109/L, median ± SD 297 ± 276 
Abnormal cytogenetics* (%) 30 of 89 (34) 
Weight loss, n (%) 33 (19) 
Hepatomegaly, n (%) 76 (44) 
Male/female (ratio) 90/82 (1.1:1) 
Circulating blasts > 1%, n (%) 60 (36) 
Immature granulocytes > 5%, n (%) 109 (64) 
Treatment regimen, n (%)  
    Chemotherapy 84 (49) 
    Androgens 33 (19) 
    Splenectomy 28 (16) 
Lille score, n (%)  
    Low 78 (45) 
    Intermediate 77 (45) 
    High 17 (10) 
IWGMRT score,* n (%)  
    Low 18 (11) 
    Intermediate-low 51 (31) 
    Intermediate-high 56 (34) 
    High 39 (24) 

SD indicates standard deviation.

*

Data were not available for all patients.

or Create an Account

Close Modal
Close Modal